NCT03549000 is a Phase 1 clinical trial of NZV930 in Non-small Cell Lung Cancer (NSCLC), sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT03549000?

NCT03549000 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT03549000?

Interventions in NCT03549000: NZV930, PDR001, NIR178.

What condition does NCT03549000 study?

NCT03549000 studies Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC).

Is NCT03549000 still recruiting?

NCT03549000 is currently terminated. Last updated 13 December 2024.

Last reviewed 2024-12-13 · How we verify

NCT03549000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Terminated Phase 1 Last updated 13 December 2024

What this trial tests

Phase 1 trial testing NZV930 in Non-small Cell Lung Cancer (NSCLC) in 127 participants. Terminated before completion.

Timeline

18 July 2018

Primary endpoint
17 October 2022

17 October 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	127
Start date	18 July 2018
Primary completion	17 October 2022
Estimated completion	17 October 2022
Sites	10 locations across Japan, United Kingdom, Canada, Australia, Singapore, United States, Spain

Drugs / interventions tested

NZV930 — full drug profile →
PDR001 — full drug profile →
NIR178 — full drug profile →

Conditions studied

Non-small Cell Lung Cancer (NSCLC) — all drugs for Non-small Cell Lung Cancer (NSCLC) →
Triple Negative Breast Cancer (TNBC) — all drugs for Triple Negative Breast Cancer (TNBC) →
Pancreatic Ductal Adenocarcinoma (PDAC) — all drugs for Pancreatic Ductal Adenocarcinoma (PDAC) →
Colorectal Cancer Microsatellite Stable (MSS) — all drugs for Colorectal Cancer Microsatellite Stable (MSS) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer (NSCLC) or Triple Negative Breast Cancer (TNBC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging therapies for glioblastoma: current state and future directions.
Rong L, Li N, Zhang Z. · · 2022 · cited 351× · PMID 35428347 · DOI 10.1186/s13046-022-02349-7
Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA, Spruck C. · · 2020 · cited 351× · PMID 33174058 · DOI 10.3892/ijo.2020.5135
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, et al · · 2019 · cited 326× · PMID 31244820 · DOI 10.3389/fimmu.2019.00925
Adenosine Metabolism: Emerging Concepts for Cancer Therapy.
Boison D, Yegutkin GG. · · 2019 · cited 251× · PMID 31821783 · DOI 10.1016/j.ccell.2019.10.007
CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C, Yin S, To KKW, Fu L. · · 2023 · cited 230× · PMID 36859386 · DOI 10.1186/s12943-023-01733-x
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Khair DO, Bax HJ, Mele S, Crescioli S, et al · · 2019 · cited 181× · PMID 30941125 · DOI 10.3389/fimmu.2019.00453
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
Extracellular ATP: A Feasible Target for Cancer Therapy.
Vultaggio-Poma V, Sarti AC, Di Virgilio F. · · 2020 · cited 174× · PMID 33212982 · DOI 10.3390/cells9112496

Verify or expand the search:

Other trials of NZV930

Trials testing the same drug.

NCT04237649 — KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors · EARLY_PHASE1 · terminated

Other recruiting trials for Non-small Cell Lung Cancer (NSCLC)

Currently open trials in the same condition.

NCT07361497 — A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec · Phase 3 · recruiting
NCT07288177 — Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
NCT07291037 — Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N · Phase 3 · recruiting
NCT07140016 — A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · Phase 1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03549000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 13 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing